托伐普坦治疗肝硬化低钠血症研究进展

doi:10.3969/j.issn.1672-5069.2018.03.048

Abstract

Abstract: Tolvaptan is a new type of non-peptide selective arginine vasopressin V2-receptor antagonist,which has the function of increasing renal solute-free water excretion and increasing serum sodium concentration. Due to the disorder of solute-free water excretion,decompensated cirrhotic patients are prone to hyponatremia. Application of tolvaptan in treatment of hyponatremia can effectively increase the concentration of sodium,reduce the risk of complications such as hepatic encephalopathy,hepatorenal syndrome,and refractory ascites. In this paper,we briefly summarized the mechanism of tolvaptan’s effects,the efficacy and safety in treatment of patients with hyponatremia.

Key words: Cirrhosis, Hyponatremia, Tolvaptan, Arginine vasopressin

Bai Mei, Mei Zhechuan. Tolvaptan in treatment of cirrhotics with hyponatremia[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(3): 481-484.

References

[1] Ginès P,Guevara M.Hyponatremia in cirrhosis:pathogenesis,clinical significance,and management. Hepatology,2008,48(3):1002-1010.
[2] Sinha VK,Ko B.Hyponatremia in cirrhosis—pathogenesis,treatment,and prognostic significance. Adv Chron Kid Dis,2015,22(5):361-367.
[3] Angeli P,Wong F,Watson H,et al.Hyponatremia in cirrhosis:results of a patient population survey.Hepatology,2006,44(6):1535-1542.
[4] Habib S,Boyer TD.Vasopressin v2-receptor antagonists in patients with cirrhosis,ascites and hyponatremia. Therap Adv Gastroenterol,2012,5(3):189-197.
[5] 向慧玲. 肝硬化低钠血症与Vaptans.世界华人消化杂志,2010,18(12):1244-1249.
[6] Ginès P,Cárdenas A.The management of ascites and hyponatremia in cirrhosis. Semin Liver Dis,2008,28(1):43-58.
[7] Kuiper JJ,de Man RA, van Buuren HR. Review article:management of ascites and associated complications in patients with cirrhosis. Aliment Pharm Ther,2007,26(suppl 2):183-193.
[8] Koealski HJ,Abelmann WH.The cardiac output at rest in Laennec’s cirrhosis. J Clin Invest,1905,32(10):1025-33.
[9] Cornel C,Sieber,Robertoj,et al.Nitric oxide mediates hyporeactivity to vasopressors in mesenteric vessels of portal hypertensive rats.Gastroenterology,1992,103(1):235-239.
[10] Sieber CC,Carloslopez-Talavera J,Groszmann RJ.Role of nitric oxide in the in vitro splanchnic vascular hyporeactivityin ascitic cirrhotic rats.Gsatroenterology,1993,104(6):1750-1754.
[11] Pizcueta P,Pique J,Fernandez M,et al.Modulation of the hyperdynamic circulation of cirrhotic rats by nitric oxide inhibition. Gastroenterology,1992,103(6):1909-1915.
[12] Pizcueta MP,Pique JM,Bosch J,et al.Effects of inhibiting nitric oxide biosynthesis on the systemic and splanchnic circulation of rats with portal hypertension.Br J Pharmacol,1992,105(1):184-190.
[13] Boyer TD.Tolvaptan and hyponatremia in a patient with cirrhosis. Hepatology,2010,51(2):699-702.
[14] Facciorusso A.Role of vaptans in the management of hydroelectrolytic imbalance in liver cirrhosis. World J Hepatol,2014,6(11):793.
[15] Fernández-Esparrach G,Sánchez-Fueyo A,Ginès P,et al.A prognostic model for predicting survival in cirrhosis with ascites. J Hepatol,2001,34(1):46-52.
[16] Biggins SW,Rodriguez HJ,Bacchetti P,et al.Serum sodium predicts mortality in patients listed for liver transplantation. Hepatology,2005,41(1):32-39.
[17] Gaglio P,Marfo K,Chiodo J.Hyponatremia in cirrhosis and end-stage liver disease:treatment with the vasopressin v2-receptor antagonist tolvaptan. Dig Dis Sci,2012,57(11):2774-2785.
[18] Thuluvath PJ, Maheshwari A,Wong F,et al.Oral v2 receptor antagonist(rwj-351647) in patients with cirrhosis and ascites:a randomized,double-blind,placebo-controlled,single ascending do-se study. Aliment Pharmacol Therap,2006,24(6):973-982.
[19] 陈平, 吴云林. 托伐普坦治疗肝硬化腹水合并低钠血症临床研究进展.内科理论与实践,2015,10(4):256-258.
[20] Rangaraian B,Binoy V,Hingmire SS,et al.Tolvaptan.South Asian J Cancer,2014,3(3):182-184.
[21] Zhang X.Clinical efficacy of tolvaptan for treatment of refractory ascites in liver cirrhosis patients. World J Gastroenterol,2014,20(32):11400.
[22] Chung SH,Jun DW,Kim KT,et al.Aquaporin-2 urinary excretion in cirrhosis: relationship to vasopressin and nitric oxide. Dig Dis Sci,2010,55(4):1135-1141.
[23] Nemerovski C,Hutchinson DJ.Treatment of hypervolemic or euvolemic hyponatremia associated with heart failure,cirrhosis,or the syndrome of inappropriate antidiuretic hormone with tolvaptan:a clinical review. Clin Ther,2010,32(6):1015-1032.
[24] Grant P.Cost effectiveness of tolvaptan.BMJ,2011,342:d1947.
[25] Cyr PL,Slawsky KA,Olchanski N,et al.Effect of serum sodium concentration and tolvaptan treatment on length of hospitalization in patients with heart failure. Am J Health Syst Pharm,2011,68(4):328-333.
[26] 阚晓,崔蕾,潘家超,等. 托伐普坦治疗肝硬化失代偿期患者稀释性低钠血症. 中华传染病杂志,2013,31(11):658-662.
[27] Fukui H. Do vasopressin v2 receptor antagonists benefit cirrhotics with refractory ascites World J Gastroenterol,2015,21(41):11584.
[28] Gheorghiade M,Gottlieb SS,Udelson JE,et al.Vasopressin v2 receptor blockade with tolvaptan versus fluid restriction in the treatment of hyponatremia. Am J Cardiol,2006,97(7):1064-1067.
[29] Cárdenas A,Ginès P,Marotta P,et al.Tolvaptan,an oral vasopressin antagonist,in the treatment of hyponatremia in cirrhosis. J Hepatol,2012,56(3):571-578.
[30] Schrier RW,Gross P,Gheorghiade M,et al.Tolvaptan,a selective oral vasopressin v2-receptor antagonist,for hyponatremia. New Engl J Med,2006,355(20):2099-2112.
[31] Yan L,Xie F,Lu J,et al.The treatment of vasopressin v2-receptor antagonists in cirrhosis patients with ascites:a meta-analysis of randomized controlled trials. Bmc Gastroenterol,2015,15(1):1-13.
[32] John S,Thuluvath PJ.Hyponatremia in cirrhosis:pathophysiology and management. World J Gastroenterol,2015,21(11):3197-3205.
[33] European association for the study of the liver. Easl clinical practice guidelines on the management of ascites,spontaneous bacterial peritonitis,and hepatorenal syndrome in cirrhosis. J Hepatol,2010,53(3):397-417.
[34] 郭皓,吴利娟,金哲,等. 血管加压素V2受体拮抗剂托伐普坦治疗肝硬化并低钠血症和肝性水肿的系统评价. 世界华人消化杂志,2016,24(6):938-946.
[35] 张翔云,杜闪闪,祖冬妮,等. 托伐普坦治疗低钠血症疗效及安全性的Meta分析.重庆医科大学学报,2016,41(9):964-970.

Tolvaptan in treatment of cirrhotics with hyponatremia

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Zhuang Ying, Lin Zhihui.. Clinical manifestations and diagnosis of portal vein thrombosis [J]. Journal of Practical Hepatology, 2019, 22(6): 765-767.
[2]	Yang Caiyong, Chen Na, Li Kui, et al.. Clinical significance of peripheral blood Treg and Th17 cells in patients with chronic hepatitis C and hepatitis C-induced liver cirrhosis [J]. Journal of Practical Hepatology, 2019, 22(6): 868-871.
[3]	Zhu Yage, Liu Jinfeng.. Therapeutic efficacy of adenosine methionine and glycyrrhizin combination in treatment of patients with alcoholic cirrhosis and its effect on serum BGP levels [J]. Journal of Practical Hepatology, 2019, 22(6): 872-875.
[4]	Wu Dan Ma Xiangying.. Insulin resistance,carotid atherosclerosis and left ventricular function in patients with NAFLD-induced liver cirrhosis [J]. Journal of Practical Hepatology, 2019, 22(6): 876-879.
[5]	Chen Meimei, Duan Xiaoyan, Cao Haixia, et al.. Improvement of clinical symptoms and serum hepatic fibrosis markers in patients with primary biliary cirrhosis by compound Biejiaruangan tablets [J]. Journal of Practical Hepatology, 2019, 22(6): 880-883.
[6]	Liu Li, Yang Lie, Chen Haiyang, et al.. Changes of hemodynamics after splenectomy combined with pericardial devascularization in patients with cirrhotic portal hypertention complicated by splenic artery steal syndrome [J]. Journal of Practical Hepatology, 2019, 22(6): 884-887.
[7]	He Zhi’an, Yu Liping, Lai Jiangqiong, et al.. Evaluation of varices bleeding and portal vein thrombosis by ARFI in patients with cirrhosis and esophagogastric varices [J]. Journal of Practical Hepatology, 2019, 22(6): 888-891.
[8]	Wang Yueyuan, Wang Yan, Zhang Dandan. Short-term efficacy of terlipressin and octreotide combination in treatment of cirrhotic patients complicated by hepatorenal syndrome [J]. Journal of Practical Hepatology, 2019, 22(5): 684-687.
[9]	Zhang Mei, Shi Xiuying, Li Linjuan, et al. Hepatic expression of interferon inducible protein -10 in patients with hepatitis B liver cirrhosis and hepatogenic diabetes mellitus [J]. Journal of Practical Hepatology, 2019, 22(5): 688-691.
[10]	Dan Zhuyongji, Liu Zhilan, Lu Yanyan, et al. Efficacy of endoscopic sequential variceal 1igation plus sclerotherapy in treatment of patients with hepatitis B-induced liver cirrhosis complicated by esophageal gastric varices bleeding [J]. Journal of Practical Hepatology, 2019, 22(5): 692-695.
[11]	Huang Hanjun, Lu Fengrong, Zhang Can. Clinical value of MRI scanning based on exchange hemodynamics model in evaluating liver cirrhosis [J]. Journal of Practical Hepatology, 2019, 22(5): 696-699.
[12]	Zhao Fangfang, Zhai Yongzhen, Feng Guohe. Efficacy and safety of autologous peripheral blood stem cell transplantation in patients with hepatitis B cirrhosis [J]. Journal of Practical Hepatology, 2019, 22(5): 700-703.
[13]	Chen Shan, Zhuang Huashuai, Xing Yixi, et al. Preventive application of meropenem in patients with liver cirrhosis complicated by upper gastrointestinal bleeding [J]. Journal of Practical Hepatology, 2019, 22(5): 704-707.
[14]	Xu Qilin, Hao Shaohuan, Ran Bo. Risk factors of portal vein thrombosis after splenectomy in patients with liver cirrhosis and portal hypertension [J]. Journal of Practical Hepatology, 2019, 22(5): 708-711.
[15]	Jin Lianghong, Li Xingjie, Guan Hongbo, et al. Clinical value of dual-energy CT iodine quantification combined with dynamic contrast-enhanced MRI in evaluating hepatic hemodynamics and liver functions in patients with hepatitis B liver cirrhosis [J]. Journal of Practical Hepatology, 2019, 22(5): 712-715.